Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016" report to their offering.

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities/Institutes.

Hepatocyte Growth Factor - Pipeline Review, H1 2016, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.

It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Companies Mentioned

  • Amgen Inc.
  • AnGes MG, Inc.
  • Kringle Pharma, Inc.
  • M3 Biotechnology, Inc.
  • Minerva Biotechnologies Corporation
  • Molecular Partners AG
  • ViroMed Co., Ltd.
  • Yooyoung Pharmaceutical Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/2c7sw2/hepatocyte_growth

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Animal Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Animal Pharmaceuticals